AURO-CEFIXIME POWDER FOR SUSPENSION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

CEFIXIME

Saatavilla:

AURO PHARMA INC

ATC-koodi:

J01DD08

INN (Kansainvälinen yleisnimi):

CEFIXIME

Annos:

100MG

Lääkemuoto:

POWDER FOR SUSPENSION

Koostumus:

CEFIXIME 100MG

Antoreitti:

ORAL

Kpl paketissa:

50ML/100ML

Prescription tyyppi:

Prescription

Terapeuttinen alue:

THIRD GENERATION CEPHALOSPORINS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0122105001; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2017-10-11

Valmisteyhteenveto

Page 1 of 33
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AURO-CEFIXIME
CEFIXIME FOR ORAL SUSPENSION, HOUSE STANDARD
100 MG / 5 ML, WHEN RECONSTITUTED
(as cefixime trihydrate)
ANTIBIOTIC
AURO PHARMA INC.
3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8,
Canada.
Date of Revision
:
November 5, 2020.
Submission Control No: 239750
Page 2 of 33
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
................................................................................3
INDICATIONS AND CLINICAL USE
......................................................................................3
CONTRAINDICATIONS
............................................................................................................4
WARNINGS AND PRECAUTIONS
..........................................................................................4
ADVERSE REACTIONS
............................................................................................................8
DRUG INTERACTIONS
..........................................................................................................10
DOSAGE AND ADMINISTRATION
......................................................................................11
OVERDOSAGE
.........................................................................................................................13
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................13
STORAGE AND STABILITY
..................................................................................................15
SPECIAL HANDLING INSTRUCTIONS
................................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.....................................................16
PART II: SCIENTIFIC INFORMATION
................................................................................17
PHARMACEUTICAL INFORMATI